Nature of the Event

Eiko LifeSciences Limited conducted its 49th Annual General Meeting (AGM) on Tuesday, 22nd September 2026 at 04:00 PM IST through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The meeting was held in compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Quantitative Figures

  • Meeting Duration: 54 minutes (concluded at 04:54 PM IST)
  • Member Attendance: 25 members attended through VC/OAVM

Dates of Action

The AGM was held on 22nd September 2026. The disclosure was filed on the same date, digitally signed at 18:43:42 +05'30'.

Parties Involved

Directors and Key Managerial Personnel Present:

  • Mr. Laxmikant Kabra (Chairman and Non-Executive Director)
  • Mr. Bhavesh Tanna (Non-Executive Director)
  • Mr. Sumukh Vartak (Whole-Time Director)
  • Mr. Rajkumar Baheti (Independent Director)
  • Ms. Kajal Kothari (Independent Director)
  • Mr. Suraj Gaikwad (Additional Independent Director)
  • Mr. Jaid Kojar (Chief Financial Officer)
  • Mr. Chintan Doshi (Company Secretary & Compliance Officer)

Other Parties Present:

  • Representatives of Statutory Auditor: M/s P S V Jain & Associates, Chartered Accountants
  • Representatives of Secretarial Auditor: M/s Shravan A. Gupta & Associates
  • Representative of Scrutiniser
  • Chairpersons of Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee

Business Transacted

The following items from the AGM notice were approved:

1. Ordinary Resolution: Adoption of Audited Standalone and Consolidated Financial Statements for the financial year ended 31st March 2026, together with Reports of Board of Directors and Auditors

2. Ordinary Resolution: Re-appointment of Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) as a Director liable to retire by rotation

3. Special Resolution: Appointment of Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as an Independent Director

4. Ordinary Resolution: Approval of Material Related Party Transactions entered into or proposed to be entered into with related parties

Proceedings Details

The meeting began with the moderator welcoming members and confirming quorum was present throughout the meeting. The chairperson addressed shareholders, sharing the company's vision and highlighting areas with exciting opportunities. A question and answer session was conducted where shareholders could share their views.

Additional Information

  • The Register of Directors and KMP, and Register of Contracts or Arrangements were made available electronically for inspection during the AGM
  • Members were instructed to send inspection requests to investor.relations@eikolifesciences.com
  • Proxy appointment facility was not applicable for this VC-based AGM
  • Helpline numbers of the RTA were provided for technical assistance

Financial Impact

Financial impact not quantified in the disclosure. The resolutions primarily concern governance matters and adoption of already published financial statements.